{{Drugbox
| Verifiedfields = changed
| Watchedfields = changed
| verifiedrevid = 458287215
| IUPAC_name = ''N''-(2,6-dimethylphenyl)-2-(2-oxopyrrolidin-1-yl)acetamide
| image = Nefiracetam.svg
| width = 150px
| image2 = Nefiracetam3d.png

<!--Clinical data-->
| tradename = 
| pregnancy_category = 
| legal_US = Unscheduled
| routes_of_administration = Oral

<!--Pharmacokinetic data-->
| bioavailability = 
| metabolism = 
| excretion = 
| elimination_half-life = 3-5 hours<ref>{{cite journal |vauthors=Fujimaki Y, Sudo K, Hakusui H, Tachizawa H, Murasaki M |title=Single- and multiple-dose pharmacokinetics of nefiracetam, a new nootropic agent, in healthy volunteers |journal=The Journal of Pharmacy and Pharmacology |volume=44 |issue=9 |pages=750–4 | date=September 1992 |pmid=1360528 |doi=10.1111/j.2042-7158.1992.tb05513.x}}</ref>

<!--Identifiers-->
| CAS_number_Ref = {{cascite|changed|??}}
| CAS_number = 77191-36-7
| ATC_prefix = none
| PubChem = 71157
| DrugBank_Ref = {{drugbankcite|correct|drugbank}}
| ChemSpiderID_Ref = {{chemspidercite|correct|chemspider}}
| ChemSpiderID = 64299
| UNII_Ref = {{fdacite|correct|FDA}}
| UNII = 1JK12GX30N
| ChEMBL_Ref = {{ebicite|correct|EBI}}
| ChEMBL = 260829

<!--Chemical data-->
| C=14 | H=18 | N=2 | O=2 
| molecular_weight = 246.305 g/mol
| SMILES = O=C2N(CC(=O)Nc1c(cccc1C)C)CCC2
| StdInChI_Ref = {{stdinchicite|correct|chemspider}}
| StdInChI = 1S/C14H18N2O2/c1-10-5-3-6-11(2)14(10)15-12(17)9-16-8-4-7-13(16)18/h3,5-6H,4,7-9H2,1-2H3,(H,15,17)
| StdInChIKey_Ref = {{stdinchicite|correct|chemspider}}
| StdInChIKey = NGHTXZCKLWZPGK-UHFFFAOYSA-N
}}

'''Nefiracetam''' is a [[nootropic]] [[antidementia]] drug of the [[racetam]] family.<ref name=NPP2005>{{cite journal|last1=Murphy|first1=Keith J|last2=Foley|first2=Andrew G|last3=O'Connell|first3=Alan W|last4=Regan|first4=Ciaran M|title=Chronic Exposure of Rats to Cognition Enhancing Drugs Produces a Neuroplastic Response Identical to that Obtained by Complex Environment Rearing|journal=Neuropsychopharmacology|date=29 June 2005|doi=10.1038/sj.npp.1300810|pmid=15988469|volume=31|pages=90–100}}</ref>

==Effects==
Nefiracetam's cytoprotective actions are mediated by enhancement of [[GABAergic]], [[cholinergic]], and [[monoaminergic]] neuronal systems. It has been shown to effectively treat apathy and improve motivation in post-stroke patients. It has been shown to exhibit antiamnesia effects for the Alzheimer's type and cerebrovascular type of dementia.<ref>{{cite journal |vauthors=Robinson RG, Jorge RE, Clarence-Smith K, Starkstein S |title=Double-blind treatment of apathy in patients with poststroke depression using nefiracetam |journal=The Journal of Neuropsychiatry and Clinical Neurosciences |volume=21 |issue=2 |pages=144–51 |year=2009 |pmid=19622685 |doi=10.1176/appi.neuropsych.21.2.144}}</ref><ref>{{cite journal |vauthors=Robinson RG, Jorge RE, Clarence-Smith K |title=Double-blind randomized treatment of poststroke depression using nefiracetam |journal=The Journal of Neuropsychiatry and Clinical Neurosciences |volume=20 |issue=2 |pages=178–84 |year=2008 |pmid=18451188 |doi=10.1176/appi.neuropsych.20.2.178}}</ref> In addition, it has also been shown to have antiamnesia effects against a wide variety of memory impairing substances, including: ethanol, chlorodiazepoxide (Librium), scopolamine, bicuculline, picrotoxin, and cycloheximide.<ref name="Effects of nefiracetam on amnesia animal models with neuronal dysfunctions">{{cite journal|vauthors=Hiramatsu M, Shiotani T, Kameyama T, Nabeshima T |title=Effects of nefiracetam on amnesia animal models with neuronal dysfunctions|journal=
Behavioural Brain Research|date=Feb 1997|volume=83|issue= 1–2|pages=107–115|doi=10.1016/s0166-4328(97)86053-6 }}</ref>

==Pharmacology==
Unlike other racetams, nefiracetam shows high [[affinity (pharmacology)|affinity]] for the [[GABAA receptor|GABA<sub>A</sub> receptor]] ([[IC50|IC<sub>50</sub>]]) = 8.5&nbsp;nM), where it is presumed to be an [[agonist]].<ref name="pmid8061686">{{cite journal | vauthors = Gouliaev AH, Senning A | title = Piracetam and other structurally related nootropics | journal = Brain Res. Brain Res. Rev. | volume = 19 | issue = 2 | pages = 180–222 | year = 1994 | pmid = 8061686 | doi = | url = }}</ref><ref name="pmid2328758">{{cite journal | vauthors = Nabeshima T, Noda Y, Tohyama K, Itoh J, Kameyama T | title = Effects of DM-9384 in a model of amnesia based on animals with GABAergic neuronal dysfunctions | journal = Eur. J. Pharmacol. | volume = 178 | issue = 2 | pages = 143–9 | year = 1990 | pmid = 2328758 | doi = | url = }}</ref> It was able to potently inhibit 80% of [[muscimol]] binding to the GABA<sub>A</sub> receptor, although it failed to displace the remaining 20% of specific muscimol binding.<ref name="pmid8061686" /><ref name="pmid2328758" /> Nefiracetam is able to reverse the [[amnesia]] caused by the GABA<sub>A</sub> receptor antagonists [[picrotoxin]] and [[bicuculline]] in mice, although it failed to prevent [[seizure]]s induced by these drugs.<ref name="pmid2328758" />

==Concerns==
Studies of long-term consumption of nefiracetam in humans and primates have shown it to have no toxicity.<ref name="M Murasaki, M Inami, J Ishigooka, H Watanabe, M Utsumi, T Matsumoto et al. 1994 3539–3587">{{cite journal|author1=M Murasaki |author2=M Inami |author3=J Ishigooka |author4=H Watanabe |author5=M Utsumi |author6=T Matsumoto |title=Phase I study on DM-9384 (nefiracetam)|journal=Jpn. Pharmacol. Ther.|year=1994|volume=22|pages=3539–3587|display-authors=etal}}</ref><ref name="E Otomo, K Kogure, S Hirai, F Goto, K Hasegawa, Y Tazaki et al. 1994 3589–3624">{{cite journal|author1=E Otomo |author2=K Kogure |author3=S Hirai |author4=F Goto |author5=K Hasegawa |author6=Y Tazaki |title=Clinical evaluation of DM-9384 in the treatment of cerebrovascular disorders: early phase II study|journal=Jpn. Pharmacol. Ther.|year=1994|issue=22|pages=3589–3624|display-authors=etal}}</ref> However, animals which metabolize nefiracetam differently from humans and primates are at risk for renal and testicular<ref>{{cite journal |pmid=12849691|year=2003|last1=Shimada|first1=M|last2=Shikanai|first2=Y|last3=Shimomura|first3=K|last4=Harada|first4=S|last5=Watanabe|first5=G|last6=Taya|first6=K|last7=Kato|first7=M|last8=Furuhama|first8=K|title=Investigation of testicular toxicity of nefiracetam, a neurotransmission enhancer, in rats|volume=143|issue=3|pages=307–15|journal=[[Toxicology letters]]|doi=10.1016/s0378-4274(03)00197-8}}</ref><ref name=Shimomura>{{cite journal|pmid=15082078|year=2004|last1=Shimomura|first1=K|last2=Shimada|first2=M|last3=Hagiwara|first3=M|last4=Harada|first4=S|last5=Kato|first5=M|last6=Furuhama|first6=K|title=Testicular toxicity induced in dogs by nefiracetam, a neutrotransmission enhancer|volume=18|issue=3|pages=423–30|doi=10.1016/j.reprotox.2004.01.008|journal=Reproductive toxicology (Elmsford, N.Y.)}}</ref> toxicity. Dogs especially are particularly sensitive, which has been shown to be caused by a specific metabolite, M-18.<ref name="Goto">{{cite journal|last1=Goto|first1=Koichi|last2=Ishii|first2=Yoshikazu|last3=Jindo|first3=Toshimasa|last4=Furuhama|first4=Kazuhisa|title=Effect of Nefiracetam, a Neurotransmission Enhancer, on Primary Uroepithelial Cells of the Canine Urinary Bladder|journal=[[Toxicological Sciences]]|date=3 March 2003|volume=72|pages=164–70|doi=10.1093/toxsci/kfg010|pmid=12604846}}</ref> Higher doses than those in dogs were needed to cause testicular toxicity in rats, although no toxicity was seen in monkeys. Additionally, there has been no evidence of toxicity during clinical trials.<ref name="M Murasaki, M Inami, J Ishigooka, H Watanabe, M Utsumi, T Matsumoto et al. 1994 3539–3587"/><ref name="E Otomo, K Kogure, S Hirai, F Goto, K Hasegawa, Y Tazaki et al. 1994 3589–3624"/>

==See also==
*[[Racetams]]

==References==
{{Reflist}}


{{Racetams}}
{{GABAA receptor modulators}}

[[Category:Racetams]]
[[Category:Acetanilides]]
[[Category:GABAA receptor agonists]]